Used as a key intermediate in the synthesis of epidermal growth factor receptor (EGFR) inhibitors for targeted cancer therapies, such as those for non-small cell lung cancer (NSCLC). This quinazoline derivative serves as a building block in medicinal chemistry to develop selective kinase inhibitors that target mutant forms of EGFR. It supports research into optimizing drug potency, selectivity, and pharmacokinetic properties, including potential blood-brain barrier penetration in final drug candidates.